Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low-density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: A pilot study

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 10, 2013, Pages 526-532

  Burchardt, Paweł ^a   Zawada, Agnieszka ^a   Tabaczewski, Piotr ^a   Naskret, Dariusz ^a   Kaczmarek, Jolanta ^b   Marcinkaniec, Justyna ^b   Wierusz Wysocka, Bogna ^a   Wysocki, Henryk ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Ginekologiczno Po o niczy Szpital Kliniczny im Heliodora wi cickiego Uniwersytetu Medycznego im Karola Marcinkowskiego   (Poland)

Author keywords

Lipid metabolism; Metformin; Type 1 diabetes

Indexed keywords

GLUCOSE; GLYCATED LOW DENSITY LIPOPROTEIN; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED LIPOPROTEINS, LDL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OBESITY; PILOT STUDY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; BLOOD; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 1; DRUG COMBINATION; DRUG EFFECTS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOPROTEINS, LDL; MALE; METFORMIN; OBESITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890300028     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.1925     Document Type: Article

References (19)

1. Burchardt P, Zawada A, Wierusz-Wysocka B. [Cardiovascular risk associated with abnormal metabolism of plasma lipoproteins in patients with diabetes mellitus]. Kardiol Pol. 2012; 70: 618-621. Polish.
2. Vergès B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 2005; 31: 429-439.
3. Younis NN, Soran H, Sharma R, et al. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res. 2010; 7: 289-295.
4. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano A, De Backer G, et al.; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769-1818.
5. Kooy A, de Jager J, Lehert P, et al. Long-term effect on metabolism and of metformin microvascullar and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009; 169: 616-625.
6. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995; 333: 541-549.
7. Nathan DM, Buse JB, Davidson MB, et al.; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009; 52: 17-30.
8. Hemmingsen B, Lund SS, Wetterslev J, Oral Vaag A. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol. 2009; 161: 1-9.
9. Vella S, Buetow L, Royle P, et al. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010; 53: 809-820.
10. Sánchez-Quesada JL, Pérez A, Caixàs A, et al. Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. J Clin Endocrinol Metab. 2001; 86: 3243-3249. (Pubitemid 32673495)
11. Jankowski M, Bała MM, Płaczkiewicz-Jankowska E, et al. Specialty outpatient care of diabetic patients in Poland - are we far from treatment targets? Rationale, design, and preliminary results of the OPTIMO study. Pol Arch Med Wewn. 2011; 121: 375-378.
12. Wegner M, Pioruńska-Stolzmann M, Araszkiewicz A, et al. Evaluation of paraoxonase 1 arylesterase activity and lipid peroxide levels in patients with type 1 diabetes. Pol Arch Med Wewn. 2011; 121: 448-454.
13. Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther. 2008; 22: 215-224.
14. Schatz H. Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control. Diabetologia. 2010; 53: 2264-2265.
15. Fedele D, Tiengo A, Nosadini R, et al. Hypolipidemic effects of metformin in hyperprebetalipoproteinemia. Diabetes Metab. 1976; 2: 127-133.
16. Montori VM, Deming J, Shah ND. How should clinicians and patients choose antihyperglycemic agents?: an evidence-based approach. Pol Arch Med Wewn. 2011; 121: 208-212.
17. Bellin C, de Wiza DH, Wiernsperger NF, Rösen P. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycaemia and metformin.Horm Metab Res. 2006; 38: 732-739. (Pubitemid 44885426)
18. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin Chim Acta. 2010; 411: 1875-1882.
19. Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol. 2011; 22: 254-261.